Healthy Aging News and ResearchClinical trial for Rapamycin (Sirolimus) in covid-19 patients

User avatar
AlbertY
Posts: 132
Joined: Mon Aug 12, 2019 4:01 pm
Location: Boston, MA

Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by AlbertY » Thu Apr 23, 2020 1:20 pm

Just noticed this clinical trial! They give the patients rapamycin 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge.


https://clinicaltrials.gov/ct2/show/NCT04341675


Ph.D. student at Harvard Medical School, doing research on aging
User avatar
AlbertY
Posts: 132
Joined: Mon Aug 12, 2019 4:01 pm
Location: Boston, MA

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by AlbertY » Thu Apr 23, 2020 1:27 pm

This is kind of cool since it is the currently MOST POTENT anti-aging drug and was used as IMMUOSUPRESSOR before people noticed its anti-aging property. Very excited to see the result of this.
Ph.D. student at Harvard Medical School, doing research on aging
Drdavid
Posts: 660
Joined: Thu Aug 15, 2019 9:59 am

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by Drdavid » Thu Apr 23, 2020 2:21 pm

Albert thank you for sharing this study. It is very exciting!
Fred

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by Fred » Thu Apr 23, 2020 4:09 pm

Thanks! Rapamycin is indeed the only molecule robustly proven to extend life in mammals.
User avatar
jocko6889
Posts: 180
Joined: Tue Jul 23, 2019 11:35 pm
Location: Tulsa, OK
Contact:

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by jocko6889 » Thu Apr 23, 2020 7:31 pm

AlbertY wrote:
Thu Apr 23, 2020 1:27 pm
This is kind of cool since it is the currently MOST POTENT anti-aging drug and was used as IMMUOSUPRESSOR before people noticed its anti-aging property. Very excited to see the result of this.
Why would you use an immunosuppressor to fight COVID-19? Isn't this a bit counter intuitive?

"Sirolimus is used with other medications to prevent rejection of a kidney transplant. This medication belongs to a class of drugs known as immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own."

https://www.webmd.com/drugs/2/drug-1770 ... al/details
Fred

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by Fred » Fri Apr 24, 2020 4:31 am

jocko6889 wrote:
Thu Apr 23, 2020 7:31 pm
AlbertY wrote:
Thu Apr 23, 2020 1:27 pm
This is kind of cool since it is the currently MOST POTENT anti-aging drug and was used as IMMUOSUPRESSOR before people noticed its anti-aging property. Very excited to see the result of this.
Why would you use an immunosuppressor to fight COVID-19? Isn't this a bit counter intuitive?

"Sirolimus is used with other medications to prevent rejection of a kidney transplant. This medication belongs to a class of drugs known as immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own."

https://www.webmd.com/drugs/2/drug-1770 ... al/details

I agree it seems counter-intuitive but a LOW DOSE of molecules with mTORC1 inhibitory function actually enhanced immune function and reduced infection rate in the elderly:

TORC1 inhibition enhances immune function and reduces infections in the elderly

Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms.

The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks.

A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation.

In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination
in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce
infections in the elderly.
https://www.researchgate.net/profile/Ha ... lderly.pdf
User avatar
AlbertY
Posts: 132
Joined: Mon Aug 12, 2019 4:01 pm
Location: Boston, MA

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by AlbertY » Fri Apr 24, 2020 11:45 am

Fred wrote:
Fri Apr 24, 2020 4:31 am
jocko6889 wrote:
Thu Apr 23, 2020 7:31 pm
AlbertY wrote:
Thu Apr 23, 2020 1:27 pm
This is kind of cool since it is the currently MOST POTENT anti-aging drug and was used as IMMUOSUPRESSOR before people noticed its anti-aging property. Very excited to see the result of this.
Why would you use an immunosuppressor to fight COVID-19? Isn't this a bit counter intuitive?

"Sirolimus is used with other medications to prevent rejection of a kidney transplant. This medication belongs to a class of drugs known as immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own."

https://www.webmd.com/drugs/2/drug-1770 ... al/details

I agree it seems counter-intuitive but a LOW DOSE of molecules with mTORC1 inhibitory function actually enhanced immune function and reduced infection rate in the elderly:

TORC1 inhibition enhances immune function and reduces infections in the elderly

Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms.

The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks.

A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation.

In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination
in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce
infections in the elderly.
https://www.researchgate.net/profile/Ha ... lderly.pdf
Yes, I agreed. Thank you Fred for explaining!
Ph.D. student at Harvard Medical School, doing research on aging
NewLifeScience
Posts: 220
Joined: Thu Aug 22, 2019 4:17 pm

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by NewLifeScience » Fri Apr 24, 2020 7:56 pm

Good stuff!

I guess i am ready to start looking for a way to get my hands on both Rapamycin and Metformin.


Love this item:
In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination
in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce
infections in the elderly.
Taking:
Resveratrol 400mg since June 2019; 600mg since October 1; 800mg since January 2020
NMN Sublingual 250mg since june 2019 500mg since September 2019
NAD+ Nasal, appx 100mg per day since September 2019; 200mg per day beginning mid November
smokinjoe
Posts: 67
Joined: Sun Sep 01, 2019 9:24 am

Re: Clinical trial for Rapamycin (Sirolimus) in covid-19 patients

Post by smokinjoe » Sat Apr 25, 2020 10:35 am

NewLifeScience wrote:
Fri Apr 24, 2020 7:56 pm
Good stuff!

I guess i am ready to start looking for a way to get my hands on both Rapamycin and Metformin.


Love this item:
In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination
in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce
infections in the elderly.
You are in Canada, correct?

How do you think you can make that happen? Visiting your GP?
Male, 41
no i don't smoke :)

taking:
NAD+ nasal since August 15, 2019
NMN powder, 125 mg per day; 625 per day since Oct 1, 2019
Resveratrol 600mg, since September 15, 2019
Post Reply Previous topicNext topic